Biosimilars

Biosimilars

Endocrinology

  • Payer value slide deck for a biosimilar in diabetes
  • Budget impact models for a biosimilar in type 1 and type 2 diabetes mellitus
  • Global value dossier, AMCP and accompanying slide sets for an insulin biosimilar

Immunology

  • Payer value slides for immunology biosimilars
  • Frequently asked questions to support the introduction of a new biosimilar in immunology
  • Frequently asked questions for biosimilar policy in immunology
  • Frequently asked questions on an immunology biosimilar for rheumatoid arthritis
  • Budget impact model for a biosimilar
  • Literature review and update to budget impact model in an immunology biosimilar
  • Updates to a US budget impact model for an immunology biosimilar
  • Update to an AMCP dossier for an immunology biosimilar
  • Originator vs. biosimilar value proposition update in immunology
  • Updates to a global value dossier, AMCP dossier and budget impact model on a rheumatoid arthritis biosimilar

Musculoskeletal diseases

  • Value message testing for a biosimilar in rheumatoid arthritis
  • Budget impact model for a biosimilar in autoimmune disease

Oncology

  • Burden of disease deck and frequently asked questions deck in breast cancer biosimilars
  • Development of a cost-calculator for a biosimilar for breast and gastric cancer
  • One-pager communication in a breast cancer biosimilar
  • Payer value deck update for a breast cancer biosimilar
  • Response to payer questions update for a breast cancer biosimilar
  • Budget impact model for a biosimilar in HER2 breast cancer
  • Budget impact model on an oncology biosimilar

Women’s health

  • Development of a value dossier, health economic model and literature review in an infertility biosimilar to support pricing and reimbursement submissions in 15 EU countries
  • Pricing updates in Europe for a biosimilar hormone treatment for female infertility

Other

  • Global value and reimbursement dossier for a biosimilar in autoimmune disease
  • Biosimilar payer communications in dermatology, gastroenterology and immunology
  • Global value dossiers and budget impact models for biosimilars in ankylosing spondylitis, Crohn’s disease, inflammatory bowel disease (IBD), osteoarthritis, psoriasis and rheumatoid arthritis
  • Manuscript on a budget impact model for a biosimilar in haematology and rheumatology